摘要
为探讨急性脑梗死患者外周血CD4^+T细胞表面PD-1、Tim-3和CTLA-4的表达并分析其与预后的关系,研究收集了2018年11月至2019年11月于郑州大学第一附属医院就诊的108例脑梗死患者与90例健康对照者外周血,FACS检测样本CD4^+T细胞表面PD-1、Tim-3和CTLA-4的表达;患者随访90 d后用改良Rankin量表评分评估预后。结果显示,急性脑梗死患者CD4+T细胞表面PD-1阳性率显著升高(P<0.001),并且预后较好组的阳性率显著高于预后较差组(P=0.020);Logistic回归分析显示CD4^+T细胞表面PD-1(OR:1.176;95%CI:1.092~1.267)与Tim-3(OR:1.471;95%CI:1.209~1.790)是患者较好预后的独立影响因素;受试者工作特征(receiver operating characteristic,ROC)曲线示CD4^+T细胞表面PD-1与Tim-3阳性率可帮助评估急性脑梗死预后,截止值分别为39.2%与10.8%。以上结果提示,CD4+T细胞表面PD-1与Tim-3的阳性率可能成为判断急性脑梗死患者预后的临床指标。
The study aims to investigate the expression of PD-1, Tim-3 and CTLA-4 on peripheral blood CD4^+T cells in patients with acute ischemic stroke, and to analyze the relationship between these immune checkpoints and clinical indicators. Peripheral blood was collected from 108 acute ischemic stroke patients and 90 healthy controls who were treated in the First Affiliated Hospital of Zhengzhou University from November 2018 to November 2019. FACS was used to measure the expre-ssion of PD-1, Tim-3 and CTLA-4 on CD4^+T cells. Prognosis was evaluated using modified Rankin Scale after 90 days of followup. The results indicated that PD-1 expression on CD4^+ T cells in patients with acute ischemic stroke was increased(P<0.001). The PD-1 expression on CD4^+T cells was higher in good recovery group than in poor recovery group(P=0.020). The results of Logistic regression indicated that PD-1(OR:1.176;95%CI:1.092-1.267) and Tim-3(OR:1.471;95%CI:1.209-1.790) were independent influence factors for good recovery. Moreover, receiver operating characteristic(ROC) results demonstrated that PD-1 and Tim-3 could predict the good recovery and the cut-off values were 39.2% and 10.8% respectively. In conclusion, the expression of PD-1 and Tim-3 on CD4^+T cells might be prognostic indicators for patients with acute ischemic stroke.
作者
何谦益
石晓娟
连晶瑶
刘莎莎
张毅
HE Qian-yi;SHI Xiao-juan;LIAN Jing-yao;LIU Sha-sha;ZHANG Yi(Biotherapy Center,the First Affiliated Hospital,Zhengzhou University,Zhengzhou 450052,China;Department of Neurology,the First Affiliated Hospital,Zhengzhou University,Zhengzhou450052,China;Cancer Center,the First Affiliated Hospital,Zhengzhou University,Zhengzhou450052,China;Henan Key Laboratory for Tumor Immunology and Biotherapy,Zhengzhou450052,China;School of Life Sciences,Zhengzhou University,Zhengzhou450001,China)
出处
《现代免疫学》
CAS
CSCD
北大核心
2020年第6期476-481,共6页
Current Immunology
基金
河南省重大科技专项(1611003101000)。
